Covance Expands Global Biologics Capabilities

Covance, a drug development services company, reported the expansion of large molecule bioanalytical space and the addition of new members to its biologics team.

The additional space will be added at its central laboratory facility in Indianapolis, Ind. The expansion, which is planned to open during the second half of 2014, will double the company’s large molecule capacity and is expected to add approximately 100 new positions over the next five years.

In addition to the expansion, the company also appointed Mike Holsapple, PhD, as Covance’s executive director of global immunotoxicology. Holsapple is a member of the Academy of Toxicological Sciences and past president of the Society of Toxicology, with more than 30 years of experience.